New drugstore levitra australia online with a lot of generic and brand medicament with cheap price and fast delivery.

Phase ii feasibility study using ch14

A joint SIOPEN & EBMT Study
Short title of clinical study
ch14.18-IL2 1021
Version: 1.1
Date of Protocol
September, 1 st 2009
EudraCT-Number 2009-015936-14
Sponsor of the Study
University Hospital Tübingen,
Geissweg 3, 72076 Tübingen
represented by board of directors (Prof. Dr. med. M.
Bamberg, Dipl.-Volksw. Gabriele Sonntag)
represented by Prof. Dr. med. R. Handgretinger

Director of the Study
Prof. Dr. med. Peter Lang
Peter Lang
Rupert Handgretinger
Ruth Ladenstein
Ulrike Pötschger
Holger Lode

Investigational drug
ch14.18/CHO antibody
Interleukin 2


Phase II feasibility study using ch14.18/CHO antibody and subcutaneous interleukin 2 after haploidentical stem cell transplantation in children with relapsed neuroblastoma Eudra-CT Number
Study Code
Principal Investigator: Peter Lang, MD, PhD
University Children’s Hospital Tübingen, Department 1 Hoppe-Seyler-Str. 1, 72076 Tübingen, Germany FAX: +49 7071 2904981 Phone: +49 7071 2985770 Email: University Hospital Tübingen, Geissweg 3, 72076 Tübingen represented by board of directors (Prof. Dr. med. M. Bamberg, Dipl.-Volksw. Gabriele Sonntag) represented by Prof. Dr. med. R. Handgretinger University Children’s Hospital Hoppe-Seyler-Str. 1 72076 Tuebingen, Germany FAX: 49 7071 2904981 Phone: 49 7071 2980894 Email: Date of Synopsis
Study Design
Number of Patients
Patient Population
Pediatric patients with relapsed neuroblastoma who previously received an allogeneic haploidentical stem cell transplantation Duration of Study
Total study: 3-4 years Individual patient: 1 year Aim of Study
To determine the safety and feasibility of the humanised chimeric 14.18 anti-GD2 monoclonal antibody produced in Chinese hamster ovary (CHO) cells (ch14.18/CHO) in combination with subcutaneous aldesleukin (IL-2, (Proleukin®)) after haploidentical stem cell transplantation in paediatric patients with relapsed neuroblastoma. Treatment Protocol
A six courses regimen consisting of a 8 hour infusion (ch14.18/CHOmAb 20 mg/m² ) for five consecutive days will be administered every 4 weeks. Interleukin 2 will be added to cycles 4-6 at days 6,8,10 (1 x 106 IU/m²/d s.c.) Participants will be premedicated with an intravenous antihistamine and ranitidine within approximately 30 minutes prior and during the infusion of the study agent Pain as an anticipated side effect is managed by a standard pain prophylaxis with Morphium hydrochloride Disease status will be evaluated after 3 and 6 courses and after 1 year. Primary Objectives
Evaluation of safety and feasibility of the chimeric 14.18 anti- GD2 monoclonal antibody (ch14.18/CHO) in combination with subcutaneous aldesleukin (IL-2, (Proleukin®) Primary endpoint is "success of treatment" defined as a patient receiving the full protocol treatment, still alive 180 days after treatment without progression and without unacceptable toxicity and acute GvHD ≥ Grade III or extensive chronic GvHD. Thus, a composite variable is used as primary endpoint: Treatment success, is defined as a patients who did not experience 1. unacceptable toxicities 2. acute GvHD ≥ Grade III or extensive chronic GvHD 3. other toxicities that did not recover to ≤ Grade 1 within 4 weeks or 4. progressive disease after 6 cycles or 5. deaths within treatment after SCT 6. withdrawal due to other reasons Secondary Objectives
To evaluate the anti-tumour responses resulting from this immunotherapy regimen through clinical assessments (radiographic and clinical measurements, including bone marrow immunohistochemistry for those research participants with marrow involvement). To evaluate pharmacokinetics of the ch14.18/CHO. To evaluate changes in NK cell activation and proliferation (immunological monitoring). Inclusion criteria
Refractory to standard treatment (i.e. refractory disease) or relapse after previous autologous or allogenic stem cell transplantation. Patient has undergone haploidentical stem cell transplantation prior to antibody infusion according to appendix IV at least 60 days prior to starting immunotherapy. Serum glutamate pyruvate transaminase (SGPT) less than 2.5 times the upper limit of normal for age and total bilirubin less than 2 times the upper limit of normal for age. D-Dimers less than 2 times the upper limit of normal. Creatinine clearance or radioisotope GFR greater than or equal to 40 ml/min/1.73m2. Cardiac shortening fraction greater than or equal to 20% by echocardiogram. Karnofsky/Lansky performance score (age appropriate) of greater than or equal to 50. Females of childbearing potential must have a negative pregnancy test. Patients of childbearing potential must agree to use an effective birth control method. Female patients who are lactating must agree to stop breast-feeding. Written informed consent is obtained, and for minors a written agreement by parents or legal guardian. All institutional and national requirements for human studies are met. Exclusion criteria
demonstration of a QTc interval > 450 milliseconds). Patients with significant psychiatric disabilities or uncontrolled seizure disorders. Patients with active infections or active peptic ulcer, unless these conditions are corrected or controlled. Patients with acute GvHD Grade III or IV or extensive chronic GvHD. Patients with clinically significant, symptomatic, pleural effusions. Patients who have had major surgery, (i.e. laparotomy or thoracotomy) within the past two weeks. Patients who will more than 12 months post haploidentical stem cell transplantation at the time of starting the first cycle of immunotherapy. Prior administration of ch14.18 antibody. HIV or Hepatitis B Surface (HBS) Ag positive. As presence of either may influence the ability if the immune system to be stimulated by this treatment. Safety variables and Unacceptable toxicities are life threatening adverse reactions defined as
stopping rules
Grade 3 or 4 toxicity using the NCI Common Toxicity Criteria, version 4.0 (Appendix II) which are in causal relationship with the study protocol. In particular, infusion of the ch14.18/CHO mAb might induce Graft versus host disease by increasing inflammatory cytokines. Occurrence of acute GvHD ≥ grade III or extensive chronic GvHD during antibody infusion will also be defined as unacceptable toxicity. Following exceptions which will not be considered unacceptab e a) Grade 3 nausea and vomiting; b) Grade 3 fever; c) Grade 3 skin toxicity that improves with treatment within 24 d) Grade 3 electrolytes, especially hyponatraemia ≤124 mEq/L in the absence of CNS symptoms and sequelae which improve with treatment within 24 hours. e) Grade 3 hypotension and hypertension; f) Grade 3 hepatic toxicity which has been present for <3 days or returns to Grade 1 or less prior to the time for next ch14.18/CHO dose; g) Grade 3 neurotoxicity, i.e. interference with function plus objective weakness, will not be DLT if transient and reversing within three days of stopping ch14.18/CHO. Subjective findings, e.g. tingling, hot or cold hands, etc., are expected and will not be unacceptable toxicity. h) Grade 4 haematologic toxicity which improves to at least Grade 2 or baseline pre-therapy values within one week following ch14.18/CHO treatment; i) Grade 3 and 4 allergic reactions, i.e. anaphylaxis, readily j) Grade 3 performance (Lansky/Karnofsky Score 30 - <50%, see k) Grade 3 capillary leak syndrome that does not persist for more These exceptions are based on the known, transient, reversible, non-dose limiting toxicities as previously published. Any patient demonstrating unacceptable toxic with ch14.18/CHO stopped. If toxicity resolves, treatment may be resumed for that patient at 50% ch14.18/CHO dose. If toxicity does not resolve, the patient has to be taken off study. If GvHD ≥ grade 1 occurs, Interleukin 2 administration will be stopped and ch14.18 will be administered as a single drug. If GvHD ≥ grade 3 occurs, ch14.18 infusion will be also stopped. If all toxicities have recovered to ≤ Grade 1 within 4 weeks (including GvHD), IL2 and ch14.18 can be given in the next course. The study will be stopped, if unexpected, live threatening (grade 4) side effects or severe acute GvHD (Grade III-IV) occurs in ≥ 5 out of 9 patients, despite dose reductions. Investigational sites
University Children’s Hospital
Hoppe-Seyler-Str. 1
72076 Tuebingen, Germany
FAX: 49 7071 2904981
Phone: 49 7071 2980894
. Anna Children’s Hospital
Kinderspitalgasse 6 1090 Vienna, Austria


Microsoft word - word_1.doc

Gesundheitsdienst Regionalarztstelle Merkblatt für Beschäftigte (Stand: 02.10/GvL/GB) Höhenkrankheit Wenn Reisen ins Hochgebirge vernünftig vorbereitet werden, besteht für Gesunde nur ein geringes Risiko. Sogar gute Erholung ist möglich. Touristen und Reisende im Hochgebirge gehen aber selbst aus Unwissenheit unnötige Risiken ein. Hierzu zählen besonders: Berg

Author's personal copy Regulatory Toxicology and Pharmacology 51 (2008) 31–36Contents lists available at ScienceDirectj o u r n a l h o m e p a g e : w w w . e l s e v i e r . c o m / l o c a t e / y r t p hRisk assessments for the insect repellents DEET and picaridinFrank B. Antwi a,1, Leslie M. Shama b,2, Robert K.D. Peterson a,*a Department of Land Resources and Environmental Scie

Copyright © 2010-2014 Pdf Physician Treatment